Cambio de paradigma en el EGFR mutado: desde las primeras mutaciones a las de resistencia - page 11

Cetuximab/afatinib

N=126 pre-treated gefinib / erlotinib advanced

EGFR

-mutant NSCLC patients

RR T790M +

- : 32%

25%, p=0.341

Median PFS : 4.7 mo

Janjigian, Cancer Discov 2014

NCT 02438722 and IFCT1503 ACE afatinib +/- cetuximab as first-line treatment

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,2,3,4,5,6,7,8,9,10 12,13,14,15,16,17,18,19,20,21,...35